Core Viewpoint - The Shanghai Stock Exchange issued a regulatory warning to Shenzhen Yahui Long Biotechnology Co., Ltd. for inaccurate and incomplete information disclosure regarding its strategic cooperation with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [1][2] Group 1: Regulatory Actions - The Shanghai Stock Exchange's management department decided to issue a regulatory warning to Yahui Long and its former board secretary Wang Mingyang due to violations of the listing rules [3] - The company is required to submit a rectification report within one month, signed by all directors and senior management, addressing the identified compliance issues [3] Group 2: Company Announcements - Yahui Long announced a strategic cooperation framework agreement with Brain Machine Star Chain, focusing on product development, market promotion, and equity investment [1] - Following media attention, Yahui Long issued a supplementary announcement clarifying that Brain Machine Star Chain's current research products are based solely on non-invasive technology and that some products are still in early development stages [1][2] Group 3: Market Reaction - The announcement led to a 6.52% increase in Yahui Long's stock price, with trading volume rising by 299% compared to the previous trading day [2] Group 4: Shareholder Actions - The controlling shareholder and chairman, Hu Kunhui, reduced his stake by 17,112,804 shares, representing 3% of the total shares, with a total transaction value of approximately 84.46 million yuan [4][5] - Another executive, Xiao Yujin, also reduced his holdings by 619,269 shares, accounting for 0.1086% of the total shares, with a total transaction value of approximately 9.20 million yuan [4][5] Group 5: Company Background - Yahui Long was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 17, 2021, with an initial public offering price of 14.80 yuan per share [6] - The company raised a total of approximately 606.8 million yuan, with net proceeds of about 541.33 million yuan after deducting issuance costs [6]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating a "Buy" rating based on recent market performance and emerging opportunities in innovative drug development [2][3]. Core Insights - The pharmaceutical sector saw a significant increase, with the Shenwan Pharmaceutical and Biological Index rising by 7.8%, outperforming the Shanghai Composite Index, which increased by 3.82% [2][3]. - The report highlights the ongoing commercialization of innovative drugs, including the oral GLP-1 medication Wegovy by Novo Nordisk, and the successful clinical trials of various RNAi therapies [11][13][18]. - The establishment of a comprehensive long-term care insurance system in China is expected to enhance the healthcare landscape, potentially benefiting the pharmaceutical sector [11][12]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 6th among 31 Shenwan first-level sub-industries, with various sub-sectors showing positive growth, such as medical devices (+10.8%) and medical research outsourcing (+11.1%) [2][5]. - The overall valuation of the pharmaceutical sector stands at 30.6 times earnings, ranking 10th among 31 Shenwan first-level industries [5][10]. Recent Key Events - The report notes the successful approval and commercialization of several new drugs, including BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which address significant medical needs [20][22]. - Collaborations in drug development are highlighted, such as the $8.88 billion partnership between Insilico Medicine and Servier focusing on oncology [21]. - The report emphasizes the potential of the brain-computer interface industry, with companies like Mindray Medical and Lepu Medical making strides in this area [24]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies and CROs, particularly those involved in the development of small nucleic acid drugs and brain-computer interface technologies [2][11]. - Specific companies to watch include Tigermed, WuXi AppTec, and Innovent Biologics, which are positioned to benefit from the recovery of the innovative drug sector [2][11].

格隆汇1月12日丨贵研铂业(600459.SH)在投资者互动平台表示，公司的孙公司贵研生物材料公司在用于 脑机接口领域的贵金属新材料加工和产品市场方面有一定的布局，部分用于脑机接口的贵金属新材料目 前尚处于实验室阶段，部分样品已提供下游客户进行放大验证，但产生的收入和利润在公司总体收入和 利润中的占比极小。 ...

Report Information - Report Title: Credit Business Weekly - How Will the A-share Market Evolve After the "Good Start" in 2026? [1][2] - Report Date: January 12, 2026 - Analyst: Xu Chi, Zhang Wenyu - Analyst Certificates: S0740519080003, S0740520120003 Market Review Market Performance - Last week, most major market indices rose, with the Science and Technology Innovation 50 Index having the largest increase of 9.80% [7][13] - Among major industry indices, the Telecommunication Services Index and Healthcare Index performed relatively well, with weekly changes of 12.04% and 7.64% respectively; the Financial Index and Consumer Staples Index performed weakly, with weekly changes of 0.41% and 1.98% respectively [7][13] - Among 30 Shenwan primary industries, 29 industries rose. The industries with large increases were National Defense and Military Industry (13.63%), Media (13.10%), and Non-ferrous Metals (8.56%); the industries with large decreases were Banks (-1.90%), Transportation (-0.23%), and Petroleum and Petrochemical (-0.29%) [7][15][16] Trading Volume - The average daily trading volume of the Wind All A Index last week was 2.851951 trillion yuan (previous value: 2.128335 trillion yuan), at a historically high level (99.30% quantile in the past three years) [18] Valuation Tracking - As of January 9, 2026, the valuation (PE_TTM) of the Wind All A Index was 23.22, up 0.90 from last week, at the 97.30% quantile in the past five years [23] - Among 30 Shenwan primary industries, the valuations (PE_TTM) of 28 industries recovered [23] Market Observation Market Trends - Last week, the A-share market continued its strong upward trend, with significant index performance, increasing trading volume, and improved profit - making effect. The main broad - based indices generally rose, and the trading volume of the Wind All A Index increased. The market's risk preference significantly recovered [5] - In the high - point market last week, technology remained the strong main line, with sectors such as media, computer, and electronics leading the gains. National Defense and Military Industry and Non - ferrous Metals also supported the market [5] Outlook - In the future, the upward trend may continue before the trading volume significantly shrinks. The market is likely to continue to revolve around the two main lines of technology segment switching and the upward demand expectation and strategic reserve of resources [6] Investment Recommendations - In the short term, the market may continue the upward trend. Investors can grasp the opportunity to allocate during market fluctuations. The robot sector is the most recommended main line, and the commercial aerospace sector may enter the "theme diffusion" stage. Other sectors such as controllable nuclear fusion, sports and consumer services, and non - ferrous metals are also worthy of attention [6] Economic Calendar - This week, important economic data include China's export year - on - year rate (in US dollars) and the US PPI year - on - year rate [25]

Core Viewpoint - The A-share market experienced a strong start in the first week of 2026, with significant inflows of leveraged funds, indicating a positive market sentiment and potential for continued investment activity [1][3]. Group 1: Market Performance - In the first week of 2026, the A-share market saw a net inflow of financing funds amounting to 857.79 billion yuan, ranking as the fifth largest weekly net inflow in A-share history [1][3]. - The total trading volume in the A-share market exceeded 30 trillion yuan on January 9, 2026, reflecting heightened market activity and investor interest [3]. Group 2: Fund Inflows - The first four days of the week recorded daily net inflows exceeding 100 billion yuan, with figures of 192.66 billion yuan, 188.87 billion yuan, 249.02 billion yuan, and 159.44 billion yuan, indicating a strong acceleration of fund entry [3]. - The electronic sector attracted the most attention from financing clients, with a net inflow of 158.12 billion yuan, significantly higher than other sectors [8]. - Non-bank financials and the computer sector also received substantial net inflows, each exceeding 60 billion yuan [9]. Group 3: Investor Behavior - Many existing clients increased their positions, primarily focusing on short-term operations and chasing market hotspots, while new account openings were not yet evident [6]. - Over 70% of the stocks saw net buying from financing clients, with seven stocks exceeding 1 billion yuan in net buying, including XW Communication and China Ping An [10]. Group 4: Future Market Outlook - Analysts suggest that the current market momentum is supported by multiple liquidity factors, including significant inflows into A500 ETF and a strengthening yuan, which reflects international confidence in China [12]. - The spring market is expected to have further room for growth, with technology sectors likely to remain a long-term focus, while value sectors may also present opportunities [12][13].

据东方财富网数据，1月12日，A股三大指数全天震荡拉升，沪指日线17连阳，突破4100点。截至收盘，沪指涨1.09%，深证成指涨1.75%，创业板指涨 1.82%。 值得注意的是，沪深京三市成交额超过3.6万亿，较上一交易日大幅放量近5000亿，创A股历史最大成交量。 盘面上，市场热点快速轮动，全市场超3900只个股上涨，连续2日超百股涨停。AI应用概念集体爆发，二十余只成分股涨停，引力传媒5天4板，省广集团、 会畅科技、粤传媒、易点天下涨停。商业航天概念反复活跃，鲁信创投11天9板，中国卫通9天5板，金风科技4连板，航天电子6天4板。可控核聚变概念延续 强势，弘讯科技、中国一重双双3连板。下跌方面，脑机接口概念下挫，美好医疗、倍益康跌超10%。 （观察者网综合东方财富网、智通财经、智通财经及其他公开资料） 本文系观察者网独家稿件，未经授权，不得转载。 据Wind统计，A股成交额突破3万亿元此前总共发生了6次，分别是2024年10月8日，2025年8月25日、8月27日、8月28日和9月18日，2026年1月9日。此前最 高成交量记录为2024年10月8日创下的3.47万亿元。 板块方面，豆包大模型、AI语料 ...

商业航天概念反复活跃，天润科技、星图测控、流金科技30CM涨停，天力复合、富士达、并行科技、中泰股份、华力创通、信科移 动、科大国创等纷纷大涨。 | 代码 名称 | 现价 涨跌 涨幅� | | --- | --- | | 920564 大润科技 | 34.93 +8.06 +30.00% | | 920116 星图测控 | 130.16 +30.03 +29.99% | | 920021 流金科技 | 9.51 +2.19 +29.92% | | 920576 天力复合 | 119.99 +23.97 +24.96% | | 920640 富士达 | 56.00 +10.00 +21.74% | | 920493 并行科技 | 187.00 +32.55 +21.07% | | 300435 中泰股份 | 31.60 +5.27 +20.02% | | 300045 华力创通 | 37.42 +6.24 +20.01% | | 688387 信科移动-U | 19.01 +3.17 +20.01% | | 300520 科大国创 | 48.52 +8.09 +20.01% | | 688333 铂力特 | 1 ...

Core Viewpoint - The article emphasizes the importance of bridging the technology chain and completing the talent chain to promote the transformation and application of brain-computer interface (BCI) technology achievements [1] Group 1: Technology Development - The Tianjin University Brain-Computer Interaction and Human-Machine Integration Haihe Laboratory focuses on non-invasive brain-computer interfaces, driving technological innovation and industrial application [1] - The laboratory has established a comprehensive layout that includes high-performance devices, chips, algorithms, platforms, system integration, and key applications [1] Group 2: Clinical Applications - The "Shengong" brain-computer interaction innovative medical device series developed by Tianjin University has been launched, covering clinical applications such as stroke rehabilitation, spinal cord injury assistance, depression treatment, and auditory disorder treatment [1] Group 3: Aerospace Applications - The laboratory has designed and developed a brain-computer interaction system for the fifth generation of space stations, successfully conducting the first "space brain-computer interface experiment" [1] - This technology has been applied in subsequent manned spaceflight missions, enhancing astronauts' functional and emotional state detection, providing critical technical support for China's next-generation medical and human factors assurance system in manned spaceflight [1]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical sector has shown weaker performance compared to the overall market, with the biopharmaceutical sector outperforming with a 7.81% increase [1]. - The brain-computer interface (BCI) industry is experiencing significant breakthroughs and commercialization opportunities, driven by favorable policies and technological advancements [2][18]. - The AI healthcare market is projected to grow substantially, with the global market size expected to increase from USD 13.7 billion in 2022 to USD 155.3 billion by 2030, reflecting a CAGR of 35.5% [23][28]. Summary by Sections Market Performance - The overall A-share market increased by 4.09%, while the biopharmaceutical sector rose by 7.81%, indicating strong sector performance [1]. - The TTM price-to-earnings ratio for the biopharmaceutical sector is at 38.96x, which is at the 85.59th percentile of the past five years [1]. Brain-Computer Interface (BCI) - The BCI market is expected to see explosive growth due to policy support, including the "14th Five-Year Plan" and the establishment of independent billing codes for BCI devices [2][18]. - Key investment opportunities include upstream hardware suppliers, midstream companies with core patents, and downstream firms that create commercial applications in rehabilitation and industrial control [2][18]. AI in Healthcare - AI is identified as a critical application area in healthcare, with various themes such as AI in drug development, multi-omics, precision diagnostics, imaging devices, and smart healthcare being highlighted for investment [3][22]. - The launch of ChatGPTHealth by OpenAI signifies a growing trend in integrating AI with healthcare applications, enhancing patient interaction with health data [29]. Company Earnings Forecasts - Several companies in the sector have been rated as "Outperform," with projected net profits for 2024 ranging from CNY 1.4 billion to CNY 116.7 billion [4]. - Notable companies include Mindray Medical (CNY 116.7 billion), WuXi AppTec (CNY 93.5 billion), and Aier Eye Hospital (CNY 35.6 billion), all showing strong growth potential [4].

Group 1 - The A-share market experienced a strong start in the first week of 2026, with a net inflow of margin financing reaching 857.79 billion yuan, ranking fifth in A-share history for single-week net inflows [1][2] - The first four days of the week saw daily net inflows exceeding 100 billion yuan, indicating a rapid influx of funds, although the fifth day showed a significant slowdown with a net inflow of only 67.81 billion yuan [2] - The electronic industry was particularly favored by margin investors, attracting a net inflow of 158.12 billion yuan, significantly higher than other sectors [5][6] Group 2 - Other sectors that received notable net inflows included non-bank financials and computers, each exceeding 60 billion yuan in net buying [6] - Over 70% of margin trading stocks experienced net buying, with seven stocks seeing net inflows exceeding 10 billion yuan, including XW Communication and China Ping An [7] - Analysts suggest that the strong performance in the A-share market is driven by multiple liquidity factors, including abnormal inflows into A500 ETF and the continuous appreciation of the yuan, reflecting international capital's restored confidence in China [8][9]